Nanobiotix Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

Nanobiotix şirketinin kazançları yıllık ortalama -1.1% oranında azalırken, Biotechs sektörünün kazançları yıllık 34.1% oranında artan oldu. Gelirler yıllık ortalama 36.3% oranında artan oldu.

Anahtar bilgiler

-1.11%

Kazanç büyüme oranı

9.55%

EPS büyüme oranı

Biotechs Sektör Büyümesi	17.04%
Gelir büyüme oranı	36.30%
Özkaynak getirisi	n/a
Net Marj	-73.52%
Son Kazanç Güncellemesi	31 Dec 2025

Yakın geçmiş performans güncellemeleri

Recent updates

Seeking Alpha • Jun 25

Nanobiotix: A Highly Speculative Bet On A Potential Radiotherapy Platform

Summary Nanobiotix is rated a strong speculative Buy, driven by risk-adjusted upside from its JNJ-1900 radioenhancer platform in partnership with Janssen. NBTX’s lead indication, head and neck cancer, offers a modeled $624M valuation, but lung cancer programs—despite higher risk—represent two-thirds of the $4.5B risk-adjusted opportunity. JNJ-1900’s platform potential is vast, with even low-probability broad adoption scenarios materially boosting valuation; upcoming clinical milestones in 2026–2027 are pivotal. Current cash runway extends into 2029, reducing near-term financing risk, while the Johnson & Johnson partnership de-risks late-stage development and supports multi-indication expansion. Current development programs target only a fraction of the potential injectable radiotherapy market, leaving substantial long-term platform optionality. Read the full article on Seeking Alpha

Seeking Alpha • Oct 18

Nanobiotix enters final agreement to restructure existing loan with EU's investment bank

French biotech Nanobiotix (NASDAQ:NBTX) on Tuesday said it had reached a final agreement with the European Investment Bank (EIB) to re-align about €30.7M in outstanding debt obligations with its expected development and commercialization timelines. The company had previously announced the agreement-in-principle with the EIB in mid-Sept. As per the newly executed final agreement, NBTX can now defer repayment of the remaining €25.3M of the loan set to be paid in two tranches up to June 2029. The restructuring agreement also includes a new milestone payment of €20M due in June 2029. U.S.-listed shares of NBTX -2.4% to $4 after hours.

Seeking Alpha • Sep 28

Nanobiotix GAAP EPS of -€0.76, revenue of €1.33M beats by €0.11M

Nanobiotix press release (NASDAQ:NBTX): 1H GAAP EPS of -€0.76. Revenue of €1.33M (+0.8% Y/Y) beats by €0.11M. Cash and Cash Equivalents: Cash and cash equivalents as of June 30, 2022, were €63.0 million, compared to €83.9 million as of December 31, 2021.

Seeking Alpha • Sep 12

Nanobiotix agrees in principle to restructure debt obligations with EU's investment bank

French biotech Nanobiotix (NASDAQ:NBTX) on Monday said it had reached an agreement in principle to restructure €30.7M in outstanding debt obligations related to its 2018 loan agreement with the European Investment Bank. NBTX said the debt restructuring was done to realign debt obligations with the company's development and commercialization timelines. The company said that execution of the amendment to the debt obligations is expected in Q4 2022 after the legal documents are finalized. "Restructuring existing debt obligations to extend the maturity date of the loan will enable Nanobiotix to drive priority development programs in 2023 by extending operating runway an additional quarter," NBTX CFO Bart Van Rhijn said in a statement. NBTX said the restructuring of the debt obligations combined with capital available through its existing equity line allows the company to extend its operating runway into Q1 2024. U.S.-listed shares of NBTX +0.2% to $4.17 in mid-day trading.

Seeking Alpha • Aug 01

French biotech Nanobiotix rebounds to post best ever 47% intraday gain

ADRs of Paris-based clinical-stage biotech Nanobiotix S.A. (NASDAQ:NBTX) recovered from a sharp selloff on Monday to record the biggest ever intraday gain thanks to strong trading volumes. Nanobiotix (NBTX) plunged nearly 30% on above-average volume to reach an all-time low on Friday. However, the stock has added ~47% on Monday, with nearly 34.4K ADRs changing hands compared to the 65-day average of ~1.1K. This quarter, Nanobiotix (NBTX) is on track to launch its first U.S. clinical trial sites in an ongoing pivotal Phase 3 trial for lead candidate NBTXR3 in head and neck squamous cell carcinoma. Its partner for the program, LianBio (LIAN) also plans to activate the first trial site and dose the first patient in Asia in H2 2022 for the candidate against the same indication.

Gelir ve Gider Dağılımı

Nanobiotix nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.

Kazanç ve Gelir Geçmişi

NasdaqGS:NBTX Gelir, gider ve kazançlar (EUR Millions )
Tarih	Gelir	Kazançlar	G+A Giderleri	Ar-Ge Giderleri
31 Dec 25	33	-24	20	23
30 Sep 25	21	-38	21	28
30 Jun 25	10	-52	21	33
31 Mar 25	1	-60	21	37
31 Dec 24	-7	-68	21	41
30 Sep 24	18	-51	21	42
30 Jun 24	42	-33	22	43
31 Mar 24	39	-37	22	40
31 Dec 23	36	-40	22	38
30 Sep 23	21	-49	21	36
30 Jun 23	7	-59	19	34
31 Mar 23	6	-58	18	33
31 Dec 22	5	-57	18	33
30 Sep 22	4	-50	18	32
30 Jun 22	3	-43	19	31
31 Mar 22	3	-45	19	31
31 Dec 21	3	-47	19	30
30 Sep 21	2	-45	19	29
30 Jun 21	2	-43	18	27
31 Mar 21	2	-39	16	26
31 Dec 20	2	-34	15	24
30 Sep 20	2	-41	16	27
30 Jun 20	2	-48	17	30
31 Mar 20	2	-49	18	30
31 Dec 19	3	-51	19	30
30 Sep 19	3	-46	17	28
30 Jun 19	3	-42	15	25
31 Mar 19	3	-36	14	23
31 Dec 18	3	-30	13	21
30 Sep 18	4	-28	12	20
30 Jun 18	4	-27	11	19
31 Mar 18	4	-26	11	19
31 Dec 17	4	-26	11	18
30 Sep 17	4	-25	12	16
30 Jun 17	4	-24	12	16
31 Mar 17	5	-23	11	16
31 Dec 16	5	-22	10	17
30 Sep 16	5	-21	10	16
30 Jun 16	5	-19	9	16
31 Mar 16	5	-18	8	15
31 Dec 15	4	-17	7	14
30 Sep 15	4	-15	7	12

Kaliteli Kazançlar: NBTX şu anda kârlı değil.

Büyüyen Kar Marjı: NBTX şu anda kârlı değil.

Serbest Nakit Akışı ve Kazanç Analizi

Geçmiş Kazanç Büyüme Analizi

Kazanç Eğilimi: NBTX kârlı değildir ve zararlar son 5 yılda yılda 1.1% oranında artmıştır.

Büyüme Hızlandırma: NBTX 'un son bir yıldaki kazanç büyümesinin 5 yıllık ortalamasıyla karşılaştırılması mümkün değil çünkü şu anda kârlı değil

Kazançlar vs. Sektör: NBTX kârlı olmadığından, geçmiş yıl kazanç büyümesinin Biotechs sektörüyle ( 64.6% ) karşılaştırılması zorlaşıyor.

Özkaynak Getirisi

Yüksek ROE: NBTX 'un yükümlülükleri varlıklarından fazla olduğundan Özsermaye Getirisi'ni hesaplamak zordur.

Varlık Getirisi

Kullanılan Sermaye Getirisi

Geçmişte güçlü performans gösteren şirketleri keşfedin

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2026/08/17 19:59
Gün Sonu Hisse Fiyatı	2026/08/17 00:00
Kazançlar	2025/12/31
Yıllık Kazançlar	2025/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına Github sayfamızdan ulaşabilirsiniz; ayrıca raporlarımızı nasıl kullanacağınıza dair kılavuzlarımız ve YouTube’da eğitim videolarımız da bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

Nanobiotix S.A. 18 Bu analistlerden 7, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
Philippa Gardner	Edison Investment Research
Jonathan Miller	Evercore ISI
Emmanuel Parot	Gilbert Dupont

Nanobiotix Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

Anahtar bilgiler

Yakın geçmiş performans güncellemeleri

Nanobiotix S.A. to Report Q4, 2025 Results on Mar 31, 2026

Nanobiotix S.A. to Report Q4, 2024 Results on Apr 02, 2025

Nanobiotix S.A. to Report Q1, 2024 Results on May 22, 2024

Nanobiotix S.A. to Report Q4, 2023 Results on Apr 24, 2024

Nanobiotix S.A. to Report Q3, 2023 Results on Nov 13, 2023

Nanobiotix S.A. to Report First Half, 2023 Results on Sep 26, 2023

Recent updates

Nanobiotix: A Highly Speculative Bet On A Potential Radiotherapy Platform

Nanobiotix S.A. has completed a Follow-on Equity Offering in the amount of €85 million.

Nanobiotix S.A. has filed a Follow-on Equity Offering in the amount of €75 million.

Nanobiotix Announces Protocol Amendment to Ongoing Global Phase 3 Head and Neck Cancer Study

Nanobiotix S.A., Annual General Meeting, Jun 09, 2026

Nanobiotix Announces New Preclinical Data Supporting Improved Systemic Bioavailability and Reduced Toxicity for Lnp-Delivered Dna Immunotherapy After Pre-Treatment with Nanoprimer Technology

Nanobiotix Presents First Data From Randomized Phase 2 Clinical Trial Evaluating JNJ-1900 (NBTXR3) In Stage 3 Inoperable Lung Cancer

Nanobiotix S.A. to Report Q4, 2025 Results on Mar 31, 2026

Nanobiotix S.A. Announces First Data from Phase 1 Study Evaluating JNJ-1900 (NBTXR3) for Patients with Esophageal Cancer

Nanobiotix Announces Regulatory Harmonization and New Composition of Matter Patent Filed for JNJ-1900 (NBTXR3)

Nanobiotix Announces Full Results from Completed Phase 1 Study Evaluating JNJ-1900 (NBTXR3) in Pancreatic Cancer

Nanobiotix Announces Presentation of Full Results from Completed Phase 1 Study Evaluating JNJ-1900 (NBTXR3) in Pancreatic Cancer Followed by Conference Call

Nanobiotix S.A., Annual General Meeting, May 19, 2025

Nanobiotix S.A. to Report Q4, 2024 Results on Apr 02, 2025

Nanobiotix Announces First Patient Dosed in A New Randomized Phase 2 Study Evaluating JNJ-1900 (NBTXR3) for Patients with Stage 3 Unresectable Non-Small Cell Lung Cancer

Nanobiotix Announces Progress in Global NBTXR3 Development Collaboration Highlighting Robust Pipeline and Pathway to Long-Term Growth

Nanobiotix S.A. to Report Q1, 2024 Results on May 22, 2024

Nanobiotix Announces US FDA Protocol Acceptance for New Randomized Phase 2 Study Evaluating Nbtxr3 for Patients with Stage Three Lung Cancer

Nanobiotix S.A. to Report Q4, 2023 Results on Apr 24, 2024

Nanobiotix S.A. announced that it has received $24.999999 million in funding from Johnson & Johnson Innovation - JJDC, Inc.